Evidence map›Paper›PMID 41686740›Full record

ArticlePloS one2026

Prognostic pan-cancer and single-cancer models: A large-scale analysis using a real-world clinico-genomic database.

Sarah F McGough, Svetlana Lyalina, Devin Incerti, Yunru Huang, Stefka Tyanova, Kieran Mace, Chris Harbron, Ryan Copping, Balasubramanian Narasimhan, Robert Tibshirani

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah F McGoughComputational Sciences, Genentech Research and Early Development, Genentech, Inc., South San Francisco, California, United States of America.ORCID https://orcid.org/0000-0003-2448-6714
Svetlana LyalinaSafety Science, Product Development, Genentech, Inc., South San Francisco, California, United States of America.
Devin IncertiData Sciences, Product Development, Genentech, Inc., South San Francisco, California, United States of America.
Yunru HuangData Sciences, Product Development, Genentech, Inc., South San Francisco, California, United States of America.
Stefka TyanovaData Sciences, Product Development, Genentech, Inc., South San Francisco, California, United States of America.
Kieran MaceData Sciences, Product Development, Genentech, Inc., South San Francisco, California, United States of America.ORCID https://orcid.org/0000-0002-8131-3118
Chris HarbronData Sciences, Product Development, F. Hoffmann-La Roche, Ltd., Welwyn Garden City, United Kingdom.
Ryan CoppingComputational Sciences, Genentech Research and Early Development, Genentech, Inc., South San Francisco, California, United States of America.
Balasubramanian NarasimhanDepartment of Statistics, Stanford University, Stanford, California, United States of America.
Robert TibshiraniDepartment of Statistics, Stanford University, Stanford, California, United States of America.

Funding

New Statistical Methods for Medical Signals and ImagesR01GM134483 · NIGMS · STANFORD UNIVERSITY · PI Iain M Johnstone · 2019 to 2026
$3.9M
NIGMS NIH HHS R01 GM134483
6 · The paper itself

Abstract

Prognostic models in oncology have a profound impact on personalized cancer care and patient profiling, but tend to be heterogeneously developed and implemented in narrow patient cohorts. Here, we develop and benchmark multiple machine learning models to predict survival in pan-cancer and 16 single-cancer settings using a de-identified clinico-genomic database of 28,079 US patients with cancer. We identify key predictors of cancer prognosis, including 15 shared across seven or more cancer types, revealing strong consistency in cancer prognostic factors. We demonstrate that pan-cancer models generally outperform or match single-cancer models in predicting survival and risk stratifying patients, especially in smaller cancer cohorts, suggesting a unique transfer learning advantage of pan-cancer models. This work demonstrates the potential of pan-cancer approaches in enhancing the accuracy and applicability of prognostic models in oncology, paving the way for more personalized and effective cancer care strategies.

Indexed as

NeoplasmsDatabases, GeneticGenomicsHumansMachine LearningPredictive Learning ModelsPrognosis

Identifiers

PMID41686740
PMCPMC12904442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.